iX Biopharma Ltd. (SG:42C) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
iX Biopharma Ltd is developing a new sublingual semaglutide wafer, iXB 401, aimed at treating diabetes and obesity through its WaferlogiX technology, with plans to out-license in China. The product is anticipated to offer better absorption and efficacy compared to existing semaglutide medications and capitalize on expiring patents by 2026. This strategic move aligns with the booming GLP-1 drug market, expected to be worth US$100 billion by 2030.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
